Unleashing a paradigm shift in early detection of pancreatic cancer
Advancing into commercial phase, Immunovia has achieved a strong launch of its first product IMMray PanCan-d which was shortly followed by backing of the largest US patient organization Pancreatic Cancer Action Network (PanCAN) and the US National Pancreas Foundation (NPF).
Such support provides real-world commercial third-party validation and should reinforce the capital market’s confidence in the test’s performance and clinical utility offer.
Read More
Vator Securities advises Sprint Bioscience on 67 MSEK Rights Issue
Vator Securities acts as Financial Adviser in connection with the transaction raising SEK 67,6 million.
Sprint Bioscience develops small-molecule first-in-class drug projects with a focus on oncology. Using fragment-based drug discovery, the company develops drug projects in a time- and resource-efficient way. These are then out-licensed to global drug companies during the preclinical phase.
Read More
Vator Securities advises Umecrine Cognition on 35 MSEK Private Placement
Vator Securities acts as Financial Adviser in connection with the transaction raising SEK 35,1 million.
Umecrine Cognition is developing golexanolone, a drug candidate with a completely new type of mechanism of action targeting the GABAA receptor in the brain.
Read More
Vator Securities advises Plastics Unbound on 30 MSEK Private Placement
Vator Securities acts as Financial Adviser in connection with the transaction raising SEK 30,3 million.
Plastics Unbound has successfully completed technical and commercial validation through Tier-1 customer trials and production applications and is now transitioning into larger volume orders.
Read More
Vator Swiss Nordic Bio 2022
VATOR SWISS NORDIC BIO 2022 – The Leading Annual European Healthcare Investor Summit in Zürich.
Vator Securities and Business Sweden & partners have the pleasure to invite you to the annual European healthcare investor conference VATOR SWISS NORDIC BIO, connecting fast growing Nordic publicly listed healthcare companies, the most exciting start-ups, and the European investor community
Read More
Vator Securities advises Xintela on 28 MSEK Directed Share Issues
Vator Securities acts as Sole Bookrunner in connection with the transactions raising SEK approximately SEK 28 million.
Xintela is developing novel stem cell therapies and antibody based targeted cancer therapies using on the integrin marker technology platform XINMARK®. The patented stem cell product XSTEM®, produced in Xintela’s own GMP-facility, is entering a clinical phase I/IIa study in 2021.
Read More
Vator Securities advises JonDeTech on 32 MSEK Directed Share Issues
Vator Securities acts as Sole Bookrunner in connection with the transaction raising SEK approximately SEK 32,4 million.
JonDeTech is a Swedish company that develops and markets patented IR sensor technology based on nanotechnology. The company’s IR sensors are down to a tenth as thick as conventional sensors, produced in plastic and can be manufactured in high volumes at a low cost, which opens for a variety of applications in, among other things, consumer electronics and mobile phones.
Read More
Vator Securities advises ZignSec on 141 MSEK Directed Share Issues
Vator Securities acts as Global Coordinator and Sole Bookrunner in connection with the transactions raising SEK approximately SEK 141 million.
The share issues are directed to a number of Swedish and international investors, including Lloyd Fonds, Altitude Capital, Consensus Asset Management and Knutsson Holdings.
Read More